abstract |
The present invention relates to a tetravalent Dengue virus vaccine, methods of inducing a neutralizing immune response against a Flavivirus such as Dengue virus 1-4. The invention also relates to methods of making a vaccine by introducing into a host cell a transgene that encodes a protein comprising Dengue domain III polypeptides, or, by purified dIII polypeptides specific for Dengue serotypes 1-4, Yellow Fever Virus, West Nile Virus, Japanese Encephalitis Virus, and Flaviviruses. |